Search Videos and More
News
Dana-Farber Research Publication 04.15.2024
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Fox Chase Cancer Center Recognizes Nobel Laureate Dr. William Kaelin With the Stanley P. Reimann Honor Award
William Kaelin Jr., MD, physician, scientist, and Nobel laureate, was recognized today at Fox Chase Cancer Center with the Stanley P. Reimann Honor Award, the center’s highest distinction. The award was presented to Kaelin while he was visiting Fox Chase to deliver a scheduled lecture.
News
Dana-Farber Cancer Institute Launches Neuro-Inclusive Oncology Care and Empowerment Program
Dana-Farber Cancer Institute launched the Neuro-Inclusive Oncology Care and Empowerment Program, a psychosocial oncology program that is specialized for adults with intellectual and/or developmental disabilities (IDD).
News
Gordon J. Freeman, PhD, Recognized with 2024 AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology
Gordon J. Freeman, PhD, of Dana-Farber Cancer Institute, will receive the 2024 AACR-Cancer Research Institute (CRI) Lloyd J. Old Award in Cancer Immunology from the American Association for Cancer Research (AACR).
News
Palliative Care Leader Receives Prestigious ASCO Special Award
News
Bispecific Antibody Therapies for Lymphoma
Since 2015, Dana-Farber researchers have been participating in clinical trials that evaluate the use of bispecific antibodies for patients with non-Hodgkin lymphoma. Three bispecific antibody therapies have been FDA approved with more on the horizon. These are exciting new medicines that rally the immune system in a powerful way to fight blood cancers. But rolling out a new type of medicine is a project of its own.
News
Dana-Farber Research Publication 03.15.2024
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Dana-Farber and Gustave Roussy to Hold Third Transatlantic Exchange: Annual Scientific Conference Dedicated to Advancing Oncology Research and Practice
Dana-Farber Cancer Institute and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the Third Transatlantic Exchange in Oncology Conference will address Liquid Biopsy as an Emerging Approach in Precision Cancer Medicine.
News
BCL2 Inhibitors: What’s the Latest Research?
BCL2 inhibitors are drugs that prompt cancer cells to die by altering the interactions among key proteins within the cells. They were clinically developed, in large part, by researchers at Dana-Farber and have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) in adults.
News
Dana-Farber Cancer Institute Researchers Join Global Cancer Grand Challenges Team Taking on Solid Tumors in Children
Dana-Farber Cancer Institute's Scott Armstrong, MD, PhD, Benjamin Ebert, MD, PhD, Eric Fischer, PhD, Cigall Kadoch, PhD, and Kimberly Stegmaier, MD, are part of a global, interdisciplinary team of researchers, called Team PROTECT, that has been selected to receive a Cancer Grand Challenges award. The award, of up to $25 million over five years, will be used to tackle solid tumors in children.2024 ASCO GU Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the clinical updates you need to know from ASCO GU 2024.
News
Laurie H. Glimcher, MD, Selected for STAT's 2024 STATUS List
Laurie H. Glimcher, MD, president and CEO of Dana-Farber Cancer Institute, is named to STAT's 2024 STATUS List, featuring 50 influential people shaping the future of health and life sciences across biotech, medicine, health care, policy, and health tech.